

Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently amended) A composition containing a mixture of human cytokines produced by

(a) culturing a human cell line (i) capable of producing cytokines, and (ii) transformed with a PKR gene and a gene that expresses a protein effective to inhibit apoptosis in the cell line, in a culture medium effective to cause ~~overproduction~~ overexpression of PKR and the anti-apoptotic protein in said mammalian cell line;

(b) treating the ~~PKR-overproducing~~ cell line to induce cytokine production; and

(c) isolating cytokines produced by said cultured, ~~PKR-overproducing~~ cell line and secreted into culture medium.

2. (Original) The composition of claim 1, which is produced by fractionating the collected cytokines to isolate cytokines having a selected affinity for anti-cytokine antibodies.

Claims 3-8 (canceled)

9. (Original) The composition of claim 1, for use in treating an inflammatory condition, wherein the cytokines isolated include two or more cytokines selected from the group consisting of IL-4, IL-5, IL-10, IL-11, IL-13, soluble TNF receptor (sTNFR), IL-1 receptor antagonist (IL-1ra).

10. (Previously presented) The composition of claim 1, wherein the isolating step includes removing from the composition, cytokine(s) selected from the group consisting of IL-1, IL-2, IL-3, IL-7, IL-8, IL-9, IL-12, TNF-alpha, TNF-beta, TGF-beta, and oncostatin.

Claims 11-24 (canceled).

25. (Currently amended) The composition of claim 1, for use as a therapeutic composition, wherein the ~~cytokines~~ cytokines isolated are selected from the group consisting of IL-1-alpha, IL-1-beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-13, IL-1 receptor antagonist (IL-1ra), IFN-alpha, IFN-beta, IFN-gamma, oncostatin, TNF-alpha, TNF-beta, soluble TNF receptor (sTNFR), GM-CSF, G-CSF, and M-CSF.

26. (previously presented) The composition of claim 25, wherein the isolated cytokines comprises IFN-alpha and IFN-beta.

27. (previously presented) The composition of claim 25, wherein the isolated cytokines comprises IFN-beta and IFN-gamma.

28. (previously presented) The composition of claim 25, wherein the isolated cytokines comprises IFN-alpha and IFN-gamma.

29. (previously presented) The composition of claim 25, wherein the cytokines isolated comprises IFN-beta and IL-10.